Literature DB >> 29254657

Cortical thickness, cortical surface area and subcortical volumes in schizophrenia and bipolar disorder patients with cannabis use.

Cecilie Bhandari Hartberg1, Elisabeth H Lange2, Trine Vik Lagerberg3, Unn K Haukvik4, Ole A Andreassen3, Ingrid Melle3, Ingrid Agartz2.   

Abstract

Cannabis is associated with increased risk for severe mental illness and is commonly used among individuals with schizophrenia or bipolar disorder. In this study we investigated associations between cannabis use and brain structures among patients with schizophrenia or bipolar disorders. Magnetic resonance imaging scans were obtained for 77 schizophrenia and 55 bipolar patients with a history of cannabis use (defined as lifetime use >10 times during one month or abuse/dependence), and 97 schizophrenia, 85 bipolar disorder patients and 277 healthy controls without any previous cannabis use. Cortical thickness, cortical surface area and subcortical volumes were compared between groups. Both hypothesis-driven region-of-interest analyses from 11 preselected brain regions in each hemisphere and exploratory point-by-point analyses were performed. We tested for diagnostic interactions and controlled for potential confounders. After controlling for confounders such as tobacco use and alcohol use disorders we found reduced cortical thickness in the caudal middle frontal gyrus compared to non-user patients and healthy controls. The findings were not significant when patients with co-morbid alcohol and illicit drug use were excluded from the analyses, but onset of cannabis use before illness onset was associated with cortical thinning in the caudal middle frontal gyrus. To conclude, we found no structural brain changes associated with cannabis use among patients with severe mental illness, but the findings indicate excess cortical thinning among those who use cannabis before illness onset. The present findings support the understanding that cannabis use is associated with limited brain effects in schizophrenia as well as bipolar disorder.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Drug abuse; MRI; Neuroimaging; Psychosis

Mesh:

Year:  2017        PMID: 29254657     DOI: 10.1016/j.euroneuro.2017.11.019

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

1.  Impact of substance use disorder on gray matter volume in schizophrenia.

Authors:  Margaret Quinn; Maureen McHugo; Kristan Armstrong; Neil Woodward; Jennifer Blackford; Stephan Heckers
Journal:  Psychiatry Res Neuroimaging       Date:  2018-08-03       Impact factor: 2.376

2.  Reduced Cortical Thickness in the Right Caudal Middle Frontal Is Associated With Symptom Severity in Betel Quid-Dependent Chewers.

Authors:  Adellah Sariah; Weidan Pu; Zhimin Xue; Zhening Liu; Xiaojun Huang
Journal:  Front Psychiatry       Date:  2020-07-10       Impact factor: 4.157

Review 3.  Adverse Effects of Recreational and Medical Cannabis.

Authors:  Ivan Urits; Karina Charipova; Kyle Gress; Nathan Li; Amnon A Berger; Elyse M Cornett; Hisham Kassem; Anh L Ngo; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2021-01-12

4.  Cannabis use and resting state functional connectivity in adolescent bipolar disorder.

Authors:  Alysha A Sultan; Megan A Hird; Mikaela K Dimick; Bradley J MacIntosh; Benjamin I Goldstein
Journal:  J Psychiatry Neurosci       Date:  2021-09       Impact factor: 6.186

5.  Regional cortical thinning in young adults with schizophrenia but not psychotic or non-psychotic bipolar I disorder.

Authors:  Douglass Godwin; Kathryn I Alpert; Lei Wang; Daniel Mamah
Journal:  Int J Bipolar Disord       Date:  2018-07-11

6.  Δ-9-Tetrahydrocannabinol treatment during adolescence and alterations in the inhibitory networks of the adult prefrontal cortex in mice subjected to perinatal NMDA receptor antagonist injection and to postweaning social isolation.

Authors:  Clara Garcia-Mompo; Yasmina Curto; Hector Carceller; Javier Gilabert-Juan; Esther Rodriguez-Flores; Ramon Guirado; Juan Nacher
Journal:  Transl Psychiatry       Date:  2020-06-01       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.